Foundation Medicine prices IPO; SeraCare bumps up diagnostics manufacturing capacity;

> Massachusetts diagnostics darling Foundation Medicine priced its IPO at about $106 million, selling more than 5.8 million shares of common stock at $18 each, well above its initial projections. Item

> Veracyte, a molecular diagnostics company, has filed plans for a proposed IPO that could reach nearly $75 million. Story

> Cancer diagnostics maker Biocept Laboratories is mulling an IPO worth up to $23 million. Story

> The EpimiRNA Consortium is getting €11.5 million ($15.5 million) in funding from the European Union to investigate molecular mechanisms, diagnostics and treatments for epilepsy. Item

> Forsite Diagnostics in the U.K. won a European Commission grant to develop a rapid molecular diagnostic test for malaria. Item

> Paraguayan and Uruguayan scientists are developing an inexpensive diagnostic for syphilis that they hope to launch by early 2014. Item

> SeraCare Life Sciences is expanding research and manufacturing capacity at its Milford, MA, headquarters so it can handle increased diagnostic manufacturing demand from its major partners. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.